BioNTech Lifts 2026 Revenue Guidance and Pays $205 Million for an FDA Fast Lane
Published on 11/14/2026 at 15:11 | Editorial boerse-global.de
BioNTech closed Wednesday's session at €77.65, up 1.0%, after a week in which the German biotech firm sharpened its full-year outlook and moved to buy regulatory speed for one of its cancer drug candidates.
The Mainz-based company now expects 2026 revenue of between €1.7 billion and €1.9 billion, having raised the midpoint of that range in early November following its third-quarter results. The guidance for adjusted research and development costs, as well as for adjusted selling and general administrative expenses, was left untouched — the brighter sales view came without any corresponding change to either spending forecast.
Quarterly Results and a Bulging Cash Pile
Revenue for the three months to the end of September came in at €1.29 billion, BioNTech reported on November 3. Under IFRS, the company booked a net profit of €184.5 million for the quarter. Revenue for the first nine months of 2026 totalled €1.51 billion.
The balance sheet remains the firm's most striking feature. Cash, cash equivalents and securities investments stood at €16.2 billion — a figure that captures not only immediately available funds but also holdings parked in marketable securities.
Should investors sell immediately? Or is it worth buying BioNTech?
$205 Million for a Priority Review Voucher
Alongside the numbers, BioNTech struck a deal with Scholar Rock to acquire a US Food and Drug Administration Priority Review Voucher for $205 million in cash. The company intends to deploy the voucher in support of a possible future marketing application for a late-stage oncology pipeline asset.
Completion hinges on customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino process. Until those boxes are ticked, the arrangement remains a proposed purchase rather than a done deal.
Roche/Genentech Takes Over a Development Programme's Costs
Separately, BioNTech said in early November that it had exercised an option within its collaboration with Roche/Genentech. From January 1, 2027, future research and development costs for the programme in question are to be borne in principle by Roche/Genentech.
Should the asset progress successfully through development and reach the market, BioNTech stands to collect royalties. The ongoing pancreatic cancer trial is to continue as planned.
Ad
BioNTech Stock: New Analysis - 14 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
